Radiotherapy Treatments for the Treatment of Thoracic District Tumors

Launched by EUROPEAN INSTITUTE OF ONCOLOGY · Mar 27, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of radiotherapy, a type of cancer treatment that uses high-energy rays, on tumors located in the chest area (thoracic region). The researchers want to understand how well these treatments work, how safe they are, and how they affect patients. They are looking for participants who have been diagnosed with various types of tumors—whether they are primary (the first tumor) or secondary (cancer that has spread from another part of the body)—and who are receiving radiotherapy for different reasons, such as to cure the cancer or to relieve symptoms.

To be eligible for the trial, participants should be between the ages of 65 and 74, must have signed consent to join, and should not be receiving radiotherapy for tumors located outside the chest area. If you join the study, you can expect to receive radiotherapy as part of your treatment and will be monitored closely by the research team to assess how well the treatment is working and how you are tolerating it. This trial is actively recruiting participants, and it aims to gather important information that could help improve treatment options for patients with thoracic tumors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• 1. Patients treated with radiotherapy for curative, palliative, neo-adjuvant, and adjuvant purposes in the thoracic region include those with:
• • Primary bone tumors,
• • Primary soft tissue tumors,
• • Primary tumors of the cardio-circulatory system,
• • Primary tumors of the lymphatic system,
• • Primary tumors of the nervous system and skin,
• • Secondary metastases from various origins localized in the thoracic region.
• • 2. Signed informed consent
• Exclusion Criteria:
• • 1. Radiotherapy in districts other than the thoracic region.